Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUZANNE REIM FANNING

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1568664480
CMS profile
343154
Location
GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$182,563.32

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUZANNE REIM FANNING

NPI 1568664480 · CMS profile ID 343154

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568664480?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUZANNE REIM FANNING, NPI 1568664480, CMS profile ID 343154. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568664480?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SUZANNE REIM FANNING, NPI 1568664480, CMS profile ID 343154. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568664480?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SUZANNE REIM FANNING, NPI 1568664480, CMS profile ID 343154, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1568664480?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $182,563.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $880.0005/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174193290 CMS
E.R. Squibb & Sons, L.L.C. $530.4205/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184767050 CMS
E.R. Squibb & Sons, L.L.C. $688.2405/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184767058 CMS
E.R. Squibb & Sons, L.L.C. $130.5005/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184767062 CMS
Genmab U.S., Inc. $25.0005/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235928337 CMS
Genmab U.S., Inc. $35.0005/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235928346 CMS
Genmab U.S., Inc. $44.0005/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928356 CMS
Genmab U.S., Inc. $186.2005/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928364 CMS
ABBVIE INC. $2,175.0005/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201836235 CMS
Genmab U.S., Inc. $272.7005/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928351 CMS
Genmab U.S., Inc. $41.0005/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235928360 CMS
E.R. Squibb & Sons, L.L.C. $1,176.8505/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1184767064 CMS
E.R. Squibb & Sons, L.L.C. $125.0005/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184767066 CMS
E.R. Squibb & Sons, L.L.C. $4,140.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184767042 CMS
ABBVIE INC. $5,075.0005/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201836233 CMS
Stemline Therapeutics Inc. $2,730.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244108495 CMS
Regeneron Healthcare Solutions, Inc. $18.3904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212917072 CMS
ABBVIE INC. $25.0104/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201836221 CMS
ABBVIE INC. $116.6804/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201836223 CMS
ABBVIE INC. $535.3804/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201836225 CMS
ABBVIE INC. $212.3604/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201836227 CMS
ABBVIE INC. $112.8804/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201836229 CMS
ABBVIE INC. $20.0004/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201836231 CMS
Genmab U.S., Inc. $4,340.0004/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1235928396 CMS
E.R. Squibb & Sons, L.L.C. $3,623.0004/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1184767038 CMS
Genmab U.S., Inc. $8.2804/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235928391 CMS
Genmab U.S., Inc. $9.8004/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928418 CMS
Genmab U.S., Inc. $18.0004/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928423 CMS
Genmab U.S., Inc. $10.7804/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235928382 CMS
Genmab U.S., Inc. $442.3604/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928387 CMS
Genmab U.S., Inc. $25.3504/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928402 CMS
Genmab U.S., Inc. $113.7204/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235928408 CMS
Genmab U.S., Inc. $39.6804/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928413 CMS
Genmab U.S., Inc. $42.7204/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928429 CMS
Genmab U.S., Inc. $174.3504/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235928434 CMS
Janssen Biotech, Inc. $1,942.5004/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174760904 CMS
E.R. Squibb & Sons, L.L.C. $86.6704/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184767040 CMS
Rigel Pharmaceuticals, Inc. $116.1004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247366998 CMS
ABBVIE INC. $3,625.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201836219 CMS
Genmab U.S., Inc. $1,860.0004/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1235928373 CMS
Janssen Biotech, Inc. $840.0003/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174751060 CMS
ABBVIE INC. $362.5003/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201836217 CMS
Stemline Therapeutics Inc. $81.7203/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244108477 CMS
Stemline Therapeutics Inc. $7,215.0003/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244108489 CMS
ABBVIE INC. $1,853.0003/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201836215 CMS
Genmab U.S., Inc. $1,860.0003/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1235928332 CMS
ABBVIE INC. $89.5903/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201836213 CMS
Rigel Pharmaceuticals, Inc. $18.2303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247370955 CMS
ABBVIE INC. $20.0003/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201836205 CMS
ABBVIE INC. $39.2103/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201836207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $190,767.73 170
PY2020 $85,121.47 56
PY2021 $105,574.59 62
PY2022 $122,268.13 97
PY2023 $122,626.62 138
PY2024 $117,635.03 99
PY2025 $182,563.32 170

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $293,215.14 28
PY2024 Principal investigator $273,898.15 55
PY2023 Principal investigator $266,899.65 53
PY2022 Principal investigator $230,178.83 90
PY2021 Principal investigator $440,992.35 115
PY2020 Principal investigator $1,220,528.29 122
PY2019 Recipient $19,291.50 3
PY2019 Principal investigator $290,529.01 106

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $14,944.80 12/04/2025 Covered Recipient Teaching Hospital
GHS GREENVILLE MEMORIAL HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202411731
Principal investigator 1 ABBVIE INC. $6,127.00 11/27/2025 Covered Recipient Teaching Hospital
GHS GREENVILLE MEMORIAL HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202411727
Principal investigator 1 Kite Pharma, Inc. $1,250.00 10/28/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212068026
Principal investigator 1 Kite Pharma, Inc. $10,500.00 10/21/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212068021
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,762.40 10/01/2025 Non-covered Recipient Entity
Us Oncology Research
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235992139
Principal investigator 1 Kite Pharma, Inc. $10,500.00 10/01/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212068016
Principal investigator 1 Incyte Corporation $97.08 09/09/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240481896
Principal investigator 1 Incyte Corporation $58.78 09/09/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240481902
Principal investigator 1 Incyte Corporation $45.80 09/09/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240481910
Principal investigator 1 Kite Pharma, Inc. $1,115.00 07/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212071584
Principal investigator 1 Eli Lilly and Company $623.61 06/11/2025 Covered Recipient Teaching Hospital
OCONEE MEMORIAL HOSPITAL
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187873361
Principal investigator 1 Incyte Corporation $2,500.00 06/04/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240481884
Principal investigator 1 Incyte Corporation $17,700.00 06/04/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240481890
Principal investigator 1 Kite Pharma, Inc. $1,250.00 05/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212071580
Principal investigator 1 GENZYME CORPORATION $20,537.00 04/14/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226080463
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute Spartanburg
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994501
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute Seneca
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994503
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute Grove Commons
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994505
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute Greer
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994507
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute Easley
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994509
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994511
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1235994513
Principal investigator 1 SANOFI US SERVICES INC. $271.00 03/26/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226085071
Principal investigator 1 Kite Pharma, Inc. $1,469.00 03/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212071576
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,064.00 02/15/2025 Non-covered Recipient Entity
Cancer Center Of The Carolinas
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235998426
Principal investigator 1 Acerta Pharma LLC $90.00 02/12/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185547125
Principal investigator 1 Kite Pharma, Inc. $1,250.00 02/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212071573
Principal investigator 1 Kite Pharma, Inc. $1,469.00 01/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212071568